Heron Therapeutics Inc. (NASDAQ:HRTX) saw unusually-strong trading volume on Monday . Approximately 2,554,433 shares were traded during trading, an increase of 355% from the previous session’s volume of 561,722 shares.The stock last traded at $17.76 and had previously closed at $16.62.

HRTX has been the subject of several recent analyst reports. Brean Capital reissued a “buy” rating on shares of Heron Therapeutics in a report on Monday, April 18th. Leerink Swann reissued a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, April 19th. Cantor Fitzgerald reissued a “buy” rating on shares of Heron Therapeutics in a report on Sunday, May 8th. Cowen and Company reissued a “buy” rating and issued a $47.00 price target on shares of Heron Therapeutics in a report on Sunday, April 17th. Finally, Noble Financial reissued a “buy” rating and issued a $51.00 price target on shares of Heron Therapeutics in a report on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $50.30.

The firm’s 50-day moving average is $17.48 and its 200 day moving average is $18.89.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.92). On average, equities analysts expect that Heron Therapeutics Inc. will post ($3.60) earnings per share for the current fiscal year.

Several large investors recently modified their holdings of the company. Swiss National Bank bought a new stake in shares of Heron Therapeutics during the fourth quarter valued at $1,100,000. GAM Holding AG boosted its position in Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock valued at $1,119,000 after buying an additional 9,400 shares during the last quarter. Russell Frank Co boosted its position in Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares during the last quarter. California State Teachers Retirement System boosted its position in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares during the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.